AbCellera Investor Presentation Deck
EARNINGS CALL SUMMARY
Q3 2023 BUSINESS UPDATE
COPYRIGHT © ABCELLERA
2
AbCellera maintains
committed to accelerating
high-value programs from
strategic partnerships, and
announced new and expanded
collaborations with new and
existing strategic partners.
AbCellera's financial position
continues to strongly support
execution of strategy,
including investments in
downstream capabilities and
pre-clinical- and early-clinical
development of assets.
●
• AbCellera expanded its existing partnership with Regeneron, with four new programs under contract.
Under its original agreement with AbCellera, Regeneron exercised its rights to advance antibody
candidates from two completed discovery programs, including one against a GPCR target.
●
AbCellera announced a new partnership with Incyte, with one new program under contract for an indication
in oncology.
●
●
AbCellera announced a new co-development partnership with Prelude to develop novel, precision
antibody-drug conjugates (ADCs) for oncology.
Business Metrics - 4 new program starts in Q3 2023, for a cumulative total of 110 with 42 unique partners;
one molecule advanced into the clinic, bringing the cumulative total to ten.
Revenue - Approximately $7 million in total revenue, driven by research fees generated by the partnership
business.
Operating Expenses -
Approximately $38 million in R&D expenses, reflecting growth in program execution, continuing platform
development, and investment in internal programs.
Approximately $4 million in S&M expenses.
Approximately $14 million in G&A expenses, reflecting good operating leverage.
Earnings - Net loss of approximately $29 million, reflective of continued investment in the business in the
absence of royalty revenues.
●
●
●
Cash Flows - With over $800 million in total cash, cash equivalents, and marketable securities as well as
unused portion of previously-secured government funding, AbCellera continues to have over $1 billion in
total available liquidity.View entire presentation